AACR 2019: Single agent umbralisib effective for relapsed slow-growing lymphoma
A study at The University of Texas MD Anderson Cancer Center revealed the investigational drug…
A study at The University of Texas MD Anderson Cancer Center revealed the investigational drug…
Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory…
Painful sores in the mouth and throat are one of the most common adverse side…
Researchers have observed for several years that people who have a history of using oral…
Mammography remains an effective method for breast cancer screening in women ages 65 and older,…
A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab…
The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumour activity with durable responses in patients…
Vaccination with as few as four tumour antigens generated antigen-specific responses, reduced intestinal tumours, and…
The investigational anticancer therapeutic LOXO-195 (now known as BAY 2731954), which targets a family of…
New studies led by University of North Carolina Lineberger Comprehensive Cancer Center researchers explore biological…